atovaquone has been researched along with Leukemia, Myeloid, Acute in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
Authors | Studies |
---|---|
Jacobs, JW; Siddon, AJ | 1 |
Devaraj, S; Horvath, TD | 1 |
Ball, ZT; Frank, DA; Gaikwad, AS; Hamada, Y; Heppler, LN; Horton, TM; Jiang, K; Krueger, MJ; Long, X; Mangubat-Medina, AE; Munoz, JO; Narayanan, P; Oyadomari, S; Rashid, R; Redell, MS; Seashore, EL; Stevens, AM; Sumazin, P; Terrell, MC; Tošić, I; Walker, SR; Xiang, M | 1 |
Anahtar, M; Bar-Natan, M; Blonquist, T; Bradner, JE; Frank, DA; Giaccone, ZT; Heppler, LN; Hetz, C; Ho, VT; Jones, N; Kim, H; Kroll, Y; Liu, S; Marineau, JJ; Neuberg, D; Shaw, D; Soiffer, RJ; Stone, RM; Toniolo, PA; Walker, SR; Xiang, M; Ye, DQ | 1 |
Fisher, S; Levy, I; Megged, O; Shalit, I; Stein, J; Yaniv, I | 1 |
5 other study(ies) available for atovaquone and Leukemia, Myeloid, Acute
Article | Year |
---|---|
Concurrent COVID-19 and babesiosis in an older, splenectomized patient.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atovaquone; Azithromycin; Babesiosis; BNT162 Vaccine; COVID-19; COVID-19 Drug Treatment; Fever; Humans; Leukemia, Myeloid, Acute; Male; Parasitemia; Remission Induction; SARS-CoV-2; Splenectomy | 2021 |
Liquid Chromatography-Tandem Mass Spectrometry-Based Therapeutic Monitoring of Plasma Atovaquone Concentrations in Pediatric Patients.
Topics: Antifungal Agents; Atovaquone; Child; Chromatography, Liquid; Humans; Leukemia, Myeloid, Acute; Plant Extracts; Pneumonia, Pneumocystis; Tandem Mass Spectrometry | 2024 |
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.
Topics: Activating Transcription Factor 4; Adolescent; Animals; Apoptosis; Atovaquone; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Disease Models, Animal; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mice; Mice, Knockout; Oxidative Phosphorylation; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atovaquone; Cell Line, Tumor; Cell Membrane; Cell Survival; Cytokine Receptor gp130; Disease Models, Animal; Down-Regulation; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Phosphotyrosine; STAT3 Transcription Factor; Treatment Outcome | 2016 |
Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation.
Topics: Anti-Infective Agents; Atovaquone; Child; Encephalitis; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Time Factors; Toxoplasmosis, Cerebral; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |